

Treanda® (bendamustine) - First-time generic

- On December 7, 2022, <u>Accord Healthcare launched</u> an <u>AP-rated</u> generic version of Cephalon/Teva's Treanda (bendamustine) injection.
 - Dr. Reddy's received FDA approval of an <u>AP-rated</u> generic version of Treanda on December 7, 2022. Launch plans are pending.
- Treanda is approved for the treatment of patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.